Results 21 to 30 of about 2,075,366 (204)

Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM

JACC
BACKGROUND Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is a progressive disease with a significant burden of recurrent cardiovascular (CV) events.
Ahmad Masri, Daniel P. Judge, Frederick L. Ruberg, Julian D. Gillmore, Justin L. Grodin, Laura Obici, Mathew S. Maurer, Marianna Fontana, Steen Hvitfeldt Poulsen, Peter van der Meer, Richard K. Cheng, Sarah A.M. Cuddy, Amrut V. Ambardekar, Kuangnan Xiong, Xiaofan Cao, Gillian Murtagh, Suresh Siddhanti, Adam Castaño, Jean-François Tamby, Jonathan C. Fox, Kevin M. Alexander, Ronald Witteles   +21 more
openaire   +2 more sources

Catheter Ablation and Device Therapy in Patients With Transthyretin Amyloid Cardiomyopathy: A Review of Non-Pharmacological Therapy. [PDF]

J Arrhythm
Transthyretin amyloid cardiomyopathy (ATTR‐CM) frequently coexists with atrial fibrillation, atrial flutter, and atrial tachycardia as well as occasionally ventricular arrhythmias and often conduction abnormalities, necessitating management for arrhythmias.
Kanazawa H, Hoshiyama T, Kaneko S, Kawahara Y, Tsuruta Y, Tsurusaki Y, Matsunaga K, Tamanoi S, Kuyama N, Usuku H, Yamamoto E, Izumiya Y, Tsujita K.   +12 more
europepmc   +2 more sources

Prevalence and incidence of amyloid transthyretin amyloidosis in the USA: insights from claims databases and electronic health records [PDF]

Open Heart
Background Amyloid transthyretin (ATTR) amyloidosis is a rare, life-threatening disease frequently manifesting with cardiomyopathy (ATTR-CM), polyneuropathy (ATTR-PN) or both (ATTR-mixed).
Xiaolei Li, Pedro A Laires, Aishwarya M Uday, Candida Cristina Quarta, Ana Martins Silva   +4 more
doaj   +2 more sources

The patient pathway in ATTR-CM in Greece and how to improve it: A multidisciplinary perspective

Hellenic Journal of Cardiology, 2023
Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed disease associated with high mortality rates and the patient journey is characterized by increased complexities.
Efstratios A. Apostolou, Anna-Maria Fontrier, Georgios K. Efthimiadis, Efstathios Kastritis, John Parissis, Panos Kanavos   +5 more
doaj   +5 more sources

Wild Type Transthyretin Amyloid Cardiomyopathy Hidden Under Ablation-Refractory Atrial Arrhythmias and the Potential Contribution of Tafamidis in Rhythm Control. [PDF]

J Arrhythm
An octogenarian man with a history of multiple catheter ablation failures for atrial fibrillation and tachycardia was diagnosed with transthyretin amyloid cardiomyopathy. After 1 year of tafamidis therapy, the patient experienced spontaneous restoration of sinus rhythm, and follow‐up image of 99mTc‐pyrophosphate scintigraphy revealed a marked decrease ...
Horie T, Nagata Y, Nozato T, Miyazaki S, Ashikaga T.   +4 more
europepmc   +2 more sources

Diversity of heart failure phenotypes in transthyretin amyloid cardiomyopathy. More than just heart failure with preserved ejection fraction [PDF]

Annals of Medicine
Introduction Current guidelines recommend suspecting transthyretin amyloid cardiomyopathy (ATTR-CM) in patients over 65 years of age with unexplained left ventricular (LV) hypertrophy in a non-dilated LV, heart failure (HF) and preserved ejection ...
Anouk Achten, Steven A. Muller, Sandra Sanders-van Wijk, Manon G. van der Meer, Pim van der Harst, Peter van Tintelen, Anneline SJM te Riele, Vanessa van Empel, Marish IFJ Oerlemans, Christian Knackstedt   +9 more
doaj   +3 more sources

Tc-99m labelled bone scintigraphy in suspected cardiac amyloidosis [PDF]

, 2023
Aims: To perform evaluation of widely embraced bone scintigraphy-based non-biopsy diagnostic criteria (NBDC) for ATTR amyloid cardiomyopathy (ATTR-CM) in clinical practice, and to refine serum free light chain (sFLC) ratio cut-offs that reliably exclude ...
Accietto A., Argiro A., Biagini E., Bomsztyk J., Caponetti A. G., Cappelli F., Fontana M., Gagliardi C., Gilbertson J., Gillmore J. D., Giovannetti A., Hawkins P. N., Hutt D. F., Ioannou A., Lachmann H. J., Law S., Longhi S., Mahmood S., Martinez-Naharro A., Massa P., Patel R., Perfetto F., Petrie A., Ponziani A., Porcari A., Rapezzi C., Rauf M. U., Ravichandran S., Razvi Y., Roczenio D., Saturi G., Serenelli M., Sguazzotti M., Starr N., Venneri L., Wechalekar A. D., Whelan C., Wisniowski B., Zampieri M.   +38 more
core   +7 more sources

Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy [PDF]

, 2023
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is often assumed to be associated with wild-type TTR genotype (ATTRwt) in elderly patients (aged >70), some of whom are not offered genetic testing. We sought to estimate the prevalence, clinical
Fontana, Marianna, Gilbertson, Janet, Gillmore, Julian D, Hawkins, Philip N, Hutt, David F, Ioannou, Adam, Lachmann, Helen, Martinez-Naharro, Ana, Masi, Ambra, Merlo, Marco, Patel, Rishi, Porcari, Aldostefano, Quarta, Candida Cristina, Rauf, Muhammad U, Razvi, Yousuf, Rowczenio, Dorota, Sinagra, Gianfranco, Venneri, Lucia, Wechalekar, Ashutosh, Whelan, Carol   +19 more
core   +4 more sources

Real-World Outcomes Among Patients in the United States Receiving Tafamidis for Transthyretin Amyloid Cardiomyopathy [PDF]

Cardiology and Therapy
Introduction Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, often fatal disease. Tafamidis demonstrated efficacy in ATTR-CM clinical trials; however, real-world disease outcomes are not thoroughly characterized.
Daniel P. Judge, Margarita Udall, Andrew M. Rosen, Neil Lamarre, Elizabeth Nagelhout, Hanh Dung Dao, Mathew S. Maurer   +6 more
doaj   +2 more sources

Clinical Penetrance of the Transthyretin V122I Variant in Older Black Patients With Heart Failure: The SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an underdiagnosed cause of heart failure (HF) among patients ≥60 years of age. Although the V122I (valine to isoleucine substitution at position 122 of the transthyretin protein) variant ...
Avni Madhani, Natalia Sabogal, Daniel Massillon, Ludwine D. Paul, Carlos Rodriguez, Denise Fine, Stephen Helmke, Morgan Winburn, Damian Kurian, Farbod Raiszadeh, Sergio Teruya, Elizabeth Cohn, Andrew J. Einstein, Edward J. Miller, Lawreen H. Connors, Mathew S. Maurer, Frederick L. Ruberg   +16 more
doaj   +1 more source